BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

February 11, 2013 8:00 AM UTC

BTG plc (LSE:BTG) was off 7.4p to 327p last week after submitting an NDA to FDA for Varisolve to treat varicose veins. The product is polidocanol endovenous microfoam.

Hemispherx Biopharma Inc. (NYSE-M:HEB) lost $0.05 (18%) to $0.23 last week after FDA issued a complete response letter for Ampligen rintatolimod to treat chronic fatigue syndrome (CFS). The agency asked for at least one additional clinical trial, complete non-clinical studies and additional data analyses. Hemispherx said it will request a meeting with FDA before submitting a formal appeal...